Hims & Hers halts compounded Wegovy copy amid federal probe
TL;DR Summary
Hims & Hers will stop selling a cheaper, compounded version of Novo Nordisk’s obesity pill Wegovy after health officials called for an investigation into possible federal-law violations; the platform had offered a $49/month compounded version, while Novo Nordisk’s Wegovy costs $149–$299/month, as FDA and HHS/DOJ actions move to curb unapproved compounded GLP-1 drugs.
- Hims & Hers will stop selling compounded version of Novo’s obesity pill statnews.com
- Hims & Hers pulls copycat weight-loss pill after threats of legal action CNBC
- Hims to stop offering GLP-1 pill after FDA warned of crackdown Reuters
- Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month investors.hims.com
- Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny Barron's
Reading Insights
Total Reads
1
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
88%
445 → 53 words
Want the full story? Read the original article
Read on statnews.com